In a major medical development, the US Food and Drug Administration (FDA) has approved the expanded use of Tezspire, developed by Amgen and AstraZeneca, for treating uncontrolled chronic sinusitis with nasal polyps in adults and adolescents aged 12 years and older.
This approval represents a significant advancement in managing a long-term condition that affects millions worldwide, causing persistent inflammation, nasal congestion, facial pain, loss of smell, and the formation of nasal polyps that severely affect breathing quality.

Originally approved for severe asthma, recent late-stage clinical trials demonstrated that Tezspire significantly reduces nasal polyp size, improves nasal airflow, and enhances quality of life. The study results showed a 98% reduction in the need for surgery and an 88% decrease in oral steroid use compared to placebo, making Tezspire a promising alternative to conventional treatments.

The medication works by targeting TSLP, a key protein involved in chronic inflammation processes associated with asthma and sinusitis.

According to Kate Shiflin, Head of Global Inflammation at Amgen, this new approval highlights the versatility of TSLP inhibition and reflects the company’s commitment to translating scientific research into meaningful clinical impact for patients.

Tezspire now enters a competitive landscape alongside Dupixent (by Sanofi and Regeneron) and similar drugs from GSK, Roche, and Novartis, ushering in a new era of hope for patients struggling with chronic sinus conditions.